Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

A. Postow, Michael; Chesney, Jason; C. Pavlick, Anna; Robert, Caroline; F. Grossmann, Kenneth; F. McDermott, David; P. Linette, Gerald; Meyer, Nicolás; K. Giguere, Jeffrey; S. Agarwala, Sanjiv; Shaheen, Montaser; S. Ernstoff, Marc; R. Minor, David; K.S. Salama, April; H. Taylor, Matthew; A. Ott, Patrick; M. Rollin, Linda; E. Horak, Christine; Gagnier, Paul; D. Wolchok, Jedd; Stephen Hodi, F.

doi:10.1056/nejmoa1414428

Public

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Published in New England Journal of Medicine • Apr 20, 2015

Authors:

Michael A. Postow

Jason Chesney

Anna C. Pavlick

Abstract

BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab was associated with a high rate of objective response, including complete responses, among patients with advanced melanoma. METHODS: In this double-blind study involving 142 ...

Subject

Ipilimumab

Nivolumab

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!